JAAD International (Mar 2023)
Comparison of real-world treatment outcomes of systemic immunomodulating therapy in atopic dermatitis patients with dark and light skin typesCapsule Summary
- Angela L. Bosma, MD,
- Wouter Ouwerkerk, PhD,
- Madeline J. Heidema, MD,
- David Prieto-Merino, PhD,
- Michael R. Ardern-Jones, MD, PhD,
- Paula Beattie, MD,
- Sara J. Brown, MD, PhD,
- John R. Ingram, MD, PhD,
- Alan D. Irvine, MD, DSc,
- Graham Ogg, MD, PhD,
- Prakash Patel, BSc,
- Nick J. Reynolds, MD, PhD,
- R.M. Ross Hearn, MD,
- Mandy Wan, PhD,
- Richard B. Warren, MD, PhD,
- Richard T. Woolf, MD, PhD,
- Ariënna M. Hyseni,
- Louise A.A. Gerbens, MD, PhD,
- Phyllis I. Spuls, MD, PhD,
- Carsten Flohr, MD, PhD,
- Maritza A. Middelkamp-Hup, MD, PhD
Affiliations
- Angela L. Bosma, MD
- Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; Correspondence to: Angela L. Bosma, MD, Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Meibergdreef 9, 1105 AZ, Amsterdam, the Netherlands.
- Wouter Ouwerkerk, PhD
- Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands; NHRIS, National Heart Centre Singapore, Singapore
- Madeline J. Heidema, MD
- Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
- David Prieto-Merino, PhD
- Faculty of Medicine, Universidad de Alcalá, Madrid, Spain; Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust and King’s College London, London, UK
- Michael R. Ardern-Jones, MD, PhD
- Clinical Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK; Department of Dermatology, University Hospitals NHS Foundation Trust, Southampton, UK
- Paula Beattie, MD
- Department of Dermatology, Royal Hospital for Children NHS Trust, Glasgow, UK
- Sara J. Brown, MD, PhD
- Centre for Genomic and Experimental Medicine, University of Edinburgh, Edinburgh, UK
- John R. Ingram, MD, PhD
- Department of Dermatology, Division of Infection & Immunity, Cardiff University, Cardiff, UK
- Alan D. Irvine, MD, DSc
- Department of Clinical Medicine, Trinity College Dublin, Dublin, Ireland
- Graham Ogg, MD, PhD
- MRC Human Immunology Unit, MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK
- Prakash Patel, BSc
- Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust and King’s College London, London, UK
- Nick J. Reynolds, MD, PhD
- Department of Dermatology, Institute of Cellular Medicine, Medical School, Newcastle University, Royal Victoria Infirmary and NIHR Newcastle Biomedical Research Centre Newcastle Hospitals NHS Foundation Trust, Newcastle upon Tyne, UK
- R.M. Ross Hearn, MD
- Department of Dermatology & Photobiology, Ninewells Hospital and Medical School, Dundee, UK
- Mandy Wan, PhD
- Pharmacy Department, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust, London, UK; Institute of Pharmaceutical Science, King's College London, London, UK
- Richard B. Warren, MD, PhD
- Dermatology Centre, Salford Royal NHS Foundation Trust, NIHR Manchester Biomedical 17 Research Centre, University of Manchester, Manchester, UK
- Richard T. Woolf, MD, PhD
- St John’s Institute of Dermatology, Guy’s and St Thomas’ NHS Foundation Trust, London, UK
- Ariënna M. Hyseni
- Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
- Louise A.A. Gerbens, MD, PhD
- Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
- Phyllis I. Spuls, MD, PhD
- Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
- Carsten Flohr, MD, PhD
- Unit for Population-Based Dermatology Research, St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust and King’s College London, London, UK
- Maritza A. Middelkamp-Hup, MD, PhD
- Department of Dermatology, Amsterdam UMC, Location Academic Medical Center, University of Amsterdam, Amsterdam Public Health Research Institute, Amsterdam Institute for Infection and Immunity, Amsterdam, the Netherlands
- Journal volume & issue
-
Vol. 10
pp. 14 – 24
Abstract
Background: Few data exist on differences in treatment effectiveness and safety in atopic dermatitis patients of different skin types. Objective: To investigate treatment outcomes of dupilumab, methotrexate, and ciclosporin, and morphological phenotypes in atopic dermatitis patients, stratified by Fitzpatrick skin type. Methods: In an observational prospective cohort study, pooling data from the Dutch TREAT (TREatment of ATopic eczema) NL (treatregister.nl) and UK-Irish A-STAR (Atopic eczema Systemic TherApy Register; astar-register.org) registries, data on morphological phenotypes and treatment outcomes were investigated. Results: A total of 235 patients were included (light skin types [LST]: Fitzpatrick skin type 1-3, n = 156 [Ethnicity, White: 94.2%]; dark skin types [DST]: skin type 4-6, n = 68 [Black African/Afro-Caribbean: 25%, South-Asian: 26.5%, and Hispanics: 0%]). DST were younger (19.5 vs 29.0 years; P .05). Limitations: Unblinded, non-randomized. Conclusion: Atopic dermatitis differs in several characteristics between LST and DST. Skin type may influence treatment effectiveness of dupilumab.
